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Nitric oxide (NO) is a gaseotransmitter, which is involved in many signaling processes in health and
disease. Three enzymes generate NO from L-arginine, with citrulline formed as a by-product: neuronal
NO synthase (nNOS or NOS1), endothelial NOS (eNOS or NOS3) and inducible NOS (iNOS or NOS2). NO is
a ligand of soluble guanylyl cyclase (sGC), an intracellular heterodimer enzyme that catalyzes the con-
version of guanosine triphosphate (GTP) to cyclic GMP (cGMP). cGMP further activates protein kinase G
that eventually reduces the smooth muscle tone in bronchi or vessels. Phosphodiesterase 5 (PDE5) de-
grades cGMP to GMP. However, NO reacts with superoxide anion (O2 ), leading to formation of the pro-
inﬂammatory molecule peroxynitrite.
Under physiological conditions, NO plays a homeostatic bronchoprotective role in healthy subjects.
In obstructive airway diseases, NO can be beneﬁcial by its bronchodilating effect, but could also be
detrimental by the formation of peroxynitrite. Since asthma and COPD are associated with increased
levels of exhaled NO, chronic inﬂammation and increased airway smooth muscle tone, the NO/sGC/cGMP
pathway could be involved in these highly prevalent obstructive airway diseases. Here we review the
involvement of NO, NO synthases, guanylyl cyclases, cGMP and phophodiesterase-5 in asthma and COPD
and potential therapeutic approaches to modulate this pathway.
© 2014 Elsevier Ltd. All rights reserved.1. Nitric oxide (NO) and NO synthases
1.1. Introduction
Nitric oxide (NO) is the ﬁrst identiﬁed gaseotransmitter, which
is involved in many diverse signaling processes including inﬂam-
mation, smooth muscle tone and neurotransmission [1,2]. Within
the respiratory tract, the main sources of NO are airway epithelial
cells and endothelial cells [3,4]. Under physiological conditions, NO
is present in the exhaled breath [5].
The synthesis of NO is catalyzed by 3 NO synthase (NOS) iso-
forms. Neuronal NOS (nNOS or NOS1) and endothelial NOS (eNOSselle).or NOS3) are constitutively expressed and their activity is regulated
by intracellular calcium concentrations and calmodulin [6,7]. In an
alternative pathway, eNOS can be activated by phosphorylation
which renders it calcium-independent [8]. In conditions of oxida-
tive stress and depletion of the co-factor BH4 (tetrahydrobiopterin),
eNOS can become uncoupled resulting in the production of su-
peroxide instead of NO [8]. Inducible NOS (iNOS or NOS2) is inde-
pendent of calcium and is regulated by cytokines and pro-
inﬂammatory stimuli [9]. However, this distinction is not that strict,
since the activity of nNOS and eNOS, also referred to as “constitu-
tive NOS (cNOS)”, can be induced by several cytokines (IL-1b, IFN-g,
TNF-a) [10,11]; while iNOS may be constitutively expressed at
certain sites including the airway epithelium [12]. No can also be
produced by various enzymes, starting from nitrite [13].
An overview of the expression of the 3 isoforms of NO synthase
in human and murine lung tissue is shown in Table 1.
Table 1
Lung expression of the 3 isoforms of NO synthase (nNOS, iNOS and eNOS) in human subjects and murine models.
Patients/model Tissue nNOS iNOS eNOS Reference
HUMAN
Patients with COPD/smokers/nonsmokers Peripheral lung tissue [ GOLD 2,3,4 (M þ P) [ GOLD 2,3,4 (M) Y GOLD 3, 4 (M) [10]
[ GOLD 1, 2,3,4 (P) Y GOLD 4 (P)
Patients with COPD/smokers/nonsmokers Bronchial submucosa ND [ Smokers, COPD (P) [ Smokers, COPD (P) [16]
Patients with severe COPD/smokers Alveolar wall ND [ Severe COPD (P)
(mainly type II pneumocytes)
ND [17]
MICE
After 8 months CS Lung homogenate ND [ (P) Y (P) [19]
Elastase-induced emphysema Lung homogenate
day 1-3-7-20
Y At d1 and d7 (M) [ (M þ P) [ (M þ P) [21]
ND ¼ not determined, M: mRNA, P:protein, CS: cigarette smoke.
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Chronic obstructive pulmonary disease (COPD) is mainly caused
by smoking cigarettes, which are an exogenous source of NO.
Ansarin et al. [14] have analyzed the exhaled nitric oxide (eNO)
levels in patients with COPD, patients with asthma and healthy
controls. Patients with COPD had higher eNO levels than healthy
controls, but lower levels than patients with asthma. Lung function
parameters such as forced expiratory volume in 1 s (FEV1) and
carbon monoxide diffusing capacity (DLCO) were inversely corre-
lated with eNO levels in patients with COPD. In contrast to patients
with asthma, the use of inhaled corticosteroids had no signiﬁcant
inﬂuence on eNO levels in patients with COPD [14]. Brindicci et al.
measured eNO at multiple expired ﬂows to make a distinction
between alveolar and bronchial NO and found that COPD is asso-
ciated with elevated alveolar NO [15].
In peripheral lung tissue and bronchial submucosa of patients
with COPD, iNOS expression was signiﬁcantly increased, irre-
spective of the GOLD stage [10,16]. Patients with severe COPD had
increased iNOSþ cells in the alveolar wall and most of these cells
were type II pneumocytes [17]. These results are in agreement with
the observed increased alveolar NO in patients with COPD [15]. In
bronchial submucosa, there was also an effect of smoking, since
smokers without airﬂow limitation had increased iNOS levels [16].
The expression of iNOS was increased in bronchial smooth muscle
cells of patients with COPD and was correlated with the degree of
airﬂow limitation [18].
The expression levels of eNOS showed a discrepancy between
the two localizations. In peripheral lung tissue, eNOS protein levels
were similar between nonsmokers, smokers without airﬂow limi-
tation and patients with COPD GOLD 1, 2 and 3. Remarkably, eNOS
levels were signiﬁcantly decreased in patients with severe COPD
GOLD 4, probably caused by the destruction of the alveolar walls
[10,19]. The levels of eNOS behaved similar to iNOS in bronchial
submucosa [16].
The levels of nNOS were increased in peripheral lung tissue of
patients with COPD GOLD stages 2, 3 and 4 compared with non-
smokers. Moreover, nNOS protein expression and disease severity
(measured by FEV1% and FEV1/FVC) were signiﬁcantly correlated
[10].
Similar to the results in human peripheral lung tissue [10], the
levels of iNOS in murine lung homogenate were increased after 8
months cigarette smoke (CS) exposure, while the levels of eNOS
were decreased [19]. In contrast to eNOS knockout mice, iNOS
knockout mice were protected against the development of CS-
induced emphysema. Treating wild-type mice with an iNOS in-
hibitor after 8 months CS exposure even reversed the lung damage
and signiﬁcantly downregulated the amount of granulocytes,
macrophages and T-lymphocytes in the lung [19].
A chronic, iNOS-related inﬂammation, hypertrophy and hyper-
plasia of alveolar type II cells and several abnormalities inpulmonary structure and function develop in mice deﬁcient in
Surfactant Protein D (SP-D) [20]. SP-D and iNOS double knockout
mice (DiNOS) maintained hyperplasia of alveolar type II cells, but
they had a reduced inﬂammation, correction of the alveolar
structural abnormalities and a restored lung function, compared
with SP-D single KO mice. So by producing NO under pathological
conditions, iNOS is involved in inﬂammation, development of
structural abnormalities and lung function [20]. These ﬁndings and
the observed increased iNOS expression in patients with COPD
suggest that the inhibition of iNOS may be a potential therapy for
patients with COPD [19,20]. However, in a murine model of
elastase-induced emphysema [21], with increased expression of
iNOS and eNOS, inhibition of iNOS decreased the amount of protein
nitration, but had no effect on inﬂammation or development of
emphysema. Inhibition of eNOS had overall no effect [21].
1.3. Asthma
In patients with asthma, especially in allergic asthmatics with
eosinophilic airway inﬂammation, the levels of nitric oxide in
exhaled air are signiﬁcantlyelevated comparedwithhealthy subjects
[22e24]. Moreover, lung function parameters such as FEV1 and DLCO
were inversely correlatedwith exhaledNO levels [14]. This increased
ﬂux of NO from the airways was signiﬁcantly decreased after inha-
lation of aminoguanidine, a relatively selective iNOS inhibitor [25].
The expression of iNOS was increased in airway epithelial cells and
inﬂammatory cells from patients with asthma compared with
healthy subjects, suggesting that this enzymeplays an important role
in the production of NO in pathological conditions [26,27]. Increased
FeNO levels are a predictor of response to inhaled corticosteroids in
patients with asthma [28]. iNOS levels in corticosteroid-treated
asthmatics were signiﬁcantly decreased compared to non-
corticosteroid treated asthmatics [29]. Treatment of asthma pa-
tients with a selective iNOS inhibitor, GW274150, signiﬁcantly
reduced FeNO levels. However, this reduction in FeNO levels did not
lead to a change inearlyor late responses to allergenchallenge, or to a
change in numbers of inﬂammatory cells in bronchoalveolar lavage
(BAL) [30]. This suggests that therapeutic treatment with an iNOS
inhibitor would not be beneﬁcial in patients with asthma.
In a murine model of allergic asthma, the pharmacological in-
hibition of iNOS by L-NAME or aminoguanidine signiﬁcantly
decreased the number of eosinophils and lymphocytes in BAL ﬂuid
in OVA-challenged mice compared with non-treated mice [31].
Also airway hyperreactivity (AHR) and mucus secretion were
signiﬁcantly decreased in OVA-challenged mice after treatment
with an iNOS inhibitor. In the same study, number of BAL cells, AHR
and mucus secretion were not different between iNOS knockout
and wild-type mice, suggesting that the lack of iNOS in these
constitutive knockout animals is probably compensated by other
mechanisms. In another study using the OVA model of allergic
asthma, no differences in AHR were observed in iNOS knockout
L.L. Dupont et al. / Pulmonary Pharmacology & Therapeutics 29 (2014) 1e6 3mice comparedwithwild-typemice. Although iNOS knockout mice
developed a similar degree of inﬂammation as the wild-type con-
trols, the deﬁciency of iNOS resulted in reduced eosinophils in BAL
and in peripheral blood [32].2. Oxidative/nitrative stress in obstructive airway diseases
Reactive oxygen species (ROS) are unstable molecules with an
unpaired electron that can be generated endogenously by mito-
chondrial electron transport during respiration or during activation
of inﬂammatory cells, and exogenously by cigarette smoke or air
pollutants. These small reactive signaling molecules can oxidize
proteins, lipids or DNA, leading to cell dysfunction and cell death.
Also reactive nitrogen species (RNS), such as the highly pro-inﬂam-
matory molecule peroxynitrite, can cause tissue injury in various
organs. Normally, they are counterbalanced by antioxidants and
rapidly removed from thebody. An imbalance betweenROS/RNS and
antioxidants leads to oxidative/nitrative stress [33e35]. Both
oxidative and nitrative stress have been linked with inﬂammatory,
obstructive airway diseases, including asthma and COPD [36,37].
Activated inﬂammatory cells such as macrophages and neutro-
phils produce increased levels of NO and ROS (superoxide (O$2 ) and
hydrogen radical (HO$)) (Fig. 1). NO rapidly reacts with O$2 to form
the pro-inﬂammatory molecule peroxynitrite. Peroxynitrite alters
the function of proteins by nitration of tyrosine residues. Currently,
3-nitrotyrosine is measured as a footprint of peroxynitrite release.
Using a new noninvasive technique, Osoata et al. were able to
measure peroxynitrite in exhaled breath condensate [38]. The
levels of peroxynitrite were signiﬁcantly higher in patients with
COPD compared with smokers and healthy controls [38].3. Soluble guanylyl cyclase
Guanylyl cyclases (GCs), members of the family of nucleotide
cyclizing enzymes, are widely distributed signal-transduction en-
zymes that catalyze the conversion of GTP to cGMP.Fig. 1. The NO/sGC/cGMP signaling pathway in obstructive airway diseases. Bronchial and
However, decreased sGC levels in COPD and asthma lead to an impaired downstream pathwa
cells such as macrophages and neutrophils also release NO and reactive oxygen species suc
soluble guanylyl cyclase, GTP: guanosine triphosphate, cGMP: cyclic guanosine monopho
peroxynitrite.Both transmembrane and soluble forms of guanylyl cyclases
exist. The transmembrane, particulate GC (pGC) acts as a receptor
for hormones such as atrial, brain (B-type) and C-type natriuretic
peptides. For further information on this transmembrane form of
GC, we refer the reader to an excellent review [39].
Soluble GC (sGC) is an intracellular receptor for gaseous ligands
(NO and to a minor extent CO) and is able to associate with the
plasma membrane through proteineprotein interactions in a Ca2þ-
dependent manner [40]. sGC is a heterodimer, consisting of an a-
subunit and a b-subunit. There are 2 forms of the a-subunit (a1 and
a2) and of the b-subunit (b1 and b2), but only a1b1 and a2b1 are
active. a1b1 and a2b1 are equally present in the brain, while a1b1 is
the most prevalent form in other tissues such as the lung [41]. Both
forms have a similar catalytic rate and sensitivity towards NO. The
C-terminal catalytic domains of both isoforms are required to form
a catalytic active centre. The b-subunit has an amino-terminal
heme-binding domain. A heme moiety that interacts with the
heme-binding domain, is essential for the sensing of NO, increasing
the cGMP production from GTP [42]. The heme moiety is a large
heterocyclic organic ring with a central metal ion (Fe). sGC is acti-
vated by nanomolar concentrations of NO in the presence of the
reduced Fe2þ (ferrous) heme moiety, while oxidized, Fe3þ (ferric)
heme is insensitive to NO (Fig. 2). Moreover, the oxidized heme
rapidly released from the protein, resulting in the exposure of an
ubiquitination site on the protein moiety, which leads to ubiquiti-
nation and proteolytic degradation of the enzyme. Similar to
oxidized heme, heme-deﬁcient sGC is unresponsive to NO. Oxida-
tion is induced by exogenous molecules, such as ODQ (1H-[1,2,4]
oxadiazolo-[4, 3-a]quinoxalin-1-one), and by endogenous mole-
cules, including reactive oxygen species (ROS) and reactive nitrogen
species (RNS) [40].
Activation of sGC induces the generation of cyclic guanosine
monophosphate (cGMP), phosphorylation of protein kinase G
(PKG) and changes in activity of effector proteins such as phos-
phodiesterases (PDE), ion channels and ion pumps [43]. This
pathway eventually leads to dilation of bronchi (bronchodilation)
or vessels (vasodilation).alveolar epithelial cells produce NO, which activates sGC under normal conditions.
y; while upregulated PDE5 levels further decrease cGMP levels. Activated inﬂammatory
h as O2 . NO and O

2 form ONOO
, leading to protein nitration. NO: nitric oxide, sGC:
sphate, PDE5: phosphodiesterase 5, PKG: protein kinase G, O2 : superoxide, ONOO
:
Fig. 2. Soluble guanylyl cyclase (sGC). Under physiological conditions, there is a balance between the reduced, NO-sensitive sGC and the oxidized, NO-insensitive sGC. Oxidative
stress and reactive oxygen species shift the balance to the oxidized form, resulting in an impaired sGC/cGMP pathway. The enzyme can even lose the hemegroup (heme-free sGC).
sGC stimulators enhance the sensitivity of the reduced enzyme to low levels of bioavailable NO, while sGC activators activate the NO-unresponsive, heme-oxidized or heme-free
enzyme. Treating smoke-exposed mice with the sGC activator BAY58-2667 reactivates the sGC/cGMP pathway, demonstrated by increased cGMP and PKG levels, and decreased
PDE-5 levels; leading to a normalized smooth muscle tone [45].
L.L. Dupont et al. / Pulmonary Pharmacology & Therapeutics 29 (2014) 1e64In patients with asthma, bronchodilation is impaired, despite
the presence of large amounts of NO in the airways that could
activate sGC and cause relaxation of the smooth muscle. In a mu-
rine model of allergic asthma, the levels of sGC a1, a2 and b1 were
reduced in the lungs, both on mRNA and protein level [44]. Mice
treated with the selective sGC inhibitor ODQ had increased airway
reactivity to methacholine compared with sham-treated mice [44].
This ﬁnding suggests that sGC could be inhibited in patients with
asthma, leading to the observed airway hyperresponsiveness. Also
in patients with COPD, the lungs contain ample amounts of NO, but
the airway tone remains elevated [14]. Patients with COPD have
decreased pulmonary mRNA and protein levels of sGC which are
correlated with disease severity [45]. The levels of sGC are also
decreased in CS-exposed mice [45] CS-exposed mice deﬁcient for
the sGC a1 subunit had a signiﬁcantly higher airway resistance
compared with CS-exposed wild-type mice (Fig. 1). These results
indicate that sGC downregulation due to CS exposure in humans
andmice, emerges as an alternative pathophysiological mechanism
of the airway hyperresponsiveness.
4. Phosphodiesterase 5 (PDE5)
Phosphodiesterase 5 (PDE5) degrades cGMP to GMP; thereby
impairing the downstream effects of cGMP (Fig. 1). Sildenaﬁl, a
short-acting inhibitor of PDE5, is already on the market for erectile
dysfunction and pulmonary arterial hypertension and induces
smooth muscle relaxation. Tadalaﬁl is a long-acting inhibitor of
PDE5. The effect of PDE5 inhibition was analyzed in guinea pigs
exposed to lipopolysaccharide (LPS) and in sensitized guinea pigs
exposed to ovalbumin [46]. Pretreatment with sildenaﬁl inhibited
the LPS-induced airway hyperreactivity, inﬂux of leukocytes and
generation of NO. Exposure to ovalbumin caused early- and late-
phase asthma responses which were not affected by sildenaﬁl.
However, AHR to histamine, leukocyte inﬂux in BAL and increased
NO metabolites in BAL were signiﬁcantly attenuated in OVA-
exposed mice after treatment with sildenaﬁl [46].In a rat model of acrolein (a component of cigarette smoke)
exposure, sildenaﬁl suppressed the acrolein-induced airway
inﬂammation and mucus production [47]. CS-exposed mice have
increased PDE5 protein levels in the lung compared with air-
exposed mice [45]. These results suggest that PDE5 inhibitors
have a therapeutic potential in airway diseases such as asthma and
COPD. However, in contrast to OVA-challenged guinea pigs [46],
OVA-challenged mice treated with sildenaﬁl did not affect airway
inﬂammation [48].
PDE5 inhibitors have not yet been tested in asthma or COPD for
their anti-inﬂammatory properties. In contrast, PDE5 inhibitors
have been investigated in patients with COPD and (concomitant)
pulmonary hypertension. Treating patients with COPD-associated
pulmonary hypertension with sildenaﬁl or tadalaﬁl did not
improve exercise capacity or quality of life [49,50].5. Therapy
Potential therapeutic approaches to modulate the NO/sGC/
cGMP pathway are activation of sGC by NO-donors, sGC stimulators
and sGC activators; or inhibition of the inﬂammation-induced
formation of NO by iNOS inhibitors.5.1. Nitric oxide donors
A reduced bioavailability and/or responsiveness to endoge-
nously produced NO contributes to the development of several
pathologies, including pulmonary diseases.
NO-donors, such as organic nitrates, release NO by spontaneous
decomposition or bioconversion, thereby activating the enzyme
sGC. However, the use of NO-donors is limited because of the po-
tential lack of response, the development of tolerance and the non-
speciﬁc interactions of NO with biomolecules (such as superoxide,
leading to formation of peroxynitrite) [40]. Moreover, in the air-
ways of patients with COPD or asthma, there are already large
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muscle relaxation.
5.2. Inducible NO synthase inhibitors
The research on the role of iNOS using animal models has given
conﬂicting results. Given the species differences in the expression
and regulation of iNOS, translational research is required to fully
elucidate the function of iNOS in obstructive airway diseases.
Treating asthma patients with the selective iNOS inhibitor
GW274150 did not lead to a change in early or late responses to
allergen challenge, or to a change in numbers of inﬂammatory cells
in BAL [30].
In healthy subjects, physiological levels of NO are produced by
eNOS and nNOS. In inﬂammatory conditions, NO levels increase
mainly due to increased iNOS activity. By inhibiting iNOS, both the
beneﬁcial effects of NO through sGC and the pro-inﬂammatory
effect of NO through formation of peroxynitrite are inhibited. The
iNOS inhibitor can reduce the levels of NO, but ROS such as su-
peroxide remain elevated. These ROS can react with the ‘constitu-
tively’ produced NO, leading to the observed unchanged 3-
nitrotyrosine (3-NT) levels in patients with asthma [30]. Indeed,
an in vitro study using human alveolar epithelial cells of patients
with severe asthma, has shown that not only nitrite, produced by
iNOS, but also H2O2, produced by dual oxidases, are important in
the formation of 3-NT [51].
Activation of the sGC/cGMP pathway on the one hand, and/or
inhibition of the NO-induced formation of pro-inﬂammatory mol-
ecules on the other hand could be more beneﬁcial.
5.3. Soluble guanylyl cyclase activators and stimulators
In several pathologies, including asthma and COPD, the NO/sGC/
cGMP pathway can be compromised by the oxidized state of sGC,
making it unresponsive to both endogenous and exogenous NO.
Therefore, an NO-independent treatment could be recommended
in these diseases [40]. Both sGC stimulators and sGC activators are
potential therapies. sGC stimulators stimulate sGC directly and
enhance the sensitivity of the reduced enzyme to low levels of
bioavailable NO (Fig. 2). While sGC stimulators are heme-depen-
dent, sGC activators activate the NO-unresponsive, heme-oxidized
or heme-free enzyme (Fig. 2). The efﬁcacy of the sGC stimulator
riociguat has already been shown in patients with pulmonary
arterial hypertension [52]. In the same line, a recent study
demonstrated that treatment of two different CS-exposed animal
models with sGC stimulators riociguat (BAY 63-2521) or BAY 41-
2272 prevent CS-induced pulmonary hypertension and emphy-
sema [53].
BAY58-2667 (or cinaciguat) is a potent NO-independent sGC
activator, replacing the weakly bound oxidized heme of sGC,
leading to activation of the enzyme; while reduced hemeis unre-
sponsive to BAY58-2667 [40]. Treating CS-exposed mice with
BAY58-2667 restored the sGC/cGMP pathway and signiﬁcantly
attenuated the CS-induced AHR compared with sham-treated mice
[45], denoting sGC as a promising pharmaceutical target of
obstructive airway diseases (Fig. 2).
6. Concluding remarks
The use of NO-donors and iNOS inhibitors as a treatment in
obstructive airway diseases has not been successful. The speciﬁc
activation of the sGC/cGMP pathway by treating patients with an
sGC activator or stimulator may be a new therapeutic approach in
obstructive lung diseases. The results of using sGC activators and
sGC stimulators in animal models of asthma and COPD arepromising, however further research is needed. Treatment by the
inhaled route should be investigated to limit potential side-effects
of systemic drug administration.
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